Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director · PRESIDENT, CEO | August 15, 2022 | August 16, 2022 |
| NOVAVAX INCNVAX · Entity 4632 | Director · President and CEO | March 02, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date August 15, 2022 · Filed August 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-08-15 · Exercise / conversion · Acquired 40,000 · Balance 40,000 Row 2 · 2022-08-15 · Sale · Disposed 39,091 · Balance 909 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.56 to $51.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-08-15 · Sale · Disposed 909 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.56 to $52.05. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2027-10-02 | Direct | 114,751 |
Reported balance
After 2022-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-15 · Exercise / conversion · Disposed 40,000 · Balance 114,751 F4: The stock option vests in five equal annual installments beginning on October 1, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.56 to $51.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.56 to $52.05. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The stock option vests in five equal annual installments beginning on October 1, 2018.
NOVAVAX INC
Report date March 02, 2026 · Filed March 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Statutory Stock Option NQSEC Table II · derivative / convertible security · Conversion / exercise price $10.11 · Expires 2036-03-02 | Direct | 551,500 |
Reported balance
After 2026-03-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 551,500 · Balance 551,500 F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing.
F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 11:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 150,167 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023726 · tm268076-3_4seq1.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,333 Underlying: Common Stock · 150,167 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 69,288 | $9.49 | $657,543.12 |
DisclosureSEC source: 0001104659-26-023726 · tm268076-3_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,680 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 150,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023726 · tm268076-3_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:37 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantNon-Statutory Stock Option NQ · Derivative | 551,500 | $9.09 Strike: $9.09 | $5,013,135.00 |
DisclosureSEC source: 0001104659-26-023074 · tm267953-4_4seq1.xml · derivative · entry 5 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,500 Underlying: Common Stock · 551,500 shares Expires 2036-03-02 F4 · derivative.exercise_date: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 02:37 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 367,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023074 · tm267953-4_4seq1.xml · derivative · entry 4 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,500 Underlying: Common Stock · 367,500 shares Expires 2036-03-02 F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 2, 2026, in each case subject to continued employment through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 9, 2026 22:08 UTC Amendment | NOVAVAX INC NVAX · Entity 4632 | GrantNon-Statutory Stock Option NQ · Derivative | 551,500 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001104659-26-025363 · tm268290-2_4aseq1.xml · derivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,500 Underlying: Common Stock · 551,500 shares Expires 2036-03-02 F1 · derivative.exercise_price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F1 · price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F2 · derivative.exercise_date: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 83,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023074 · tm267953-4_4seq1.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2033-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 1, 2024, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 38,450 | $10.14 | $389,883.00 |
DisclosureSEC source: 0001104659-26-023074 · tm267953-4_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,680 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:37 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023074 · tm267953-4_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 00:57 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 83,197 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-006721 · tm264124-1_4seq1.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,197 shares Expires 2033-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 00:57 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 39,132 | $9.17 | $358,840.44 |
DisclosureSEC source: 0001104659-26-006721 · tm264124-1_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,797 Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 00:57 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 83,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-006721 · tm264124-1_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Restricted Stock Units RSU · Derivative | 450,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000304 · primary_01.xml · derivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,500 Underlying: Common Stock · 450,500 shares Expires 2035-03-03 F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Non-statutory Stock Option NQ · Derivative | 676,000 | $7.87 Strike: $7.87 | $5,320,120.00 |
DisclosureSEC source: 0001593968-25-000304 · primary_01.xml · derivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,000 Underlying: Common Stock · 676,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:42 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 83,334 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000286 · primary_01.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock · 83,334 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:42 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 38,451 | $8.33 | $320,296.83 |
DisclosureSEC source: 0001593968-25-000286 · primary_01.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,732 Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:42 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 83,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000286 · primary_01.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:19 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 83,196 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000137 · primary_01.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,197 Underlying: Common Stock · 83,196 shares Expires 2033-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:19 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 38,873 | $9.55 | $371,237.15 |
DisclosureSEC source: 0001593968-25-000137 · primary_01.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,849 Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 23:19 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 83,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000137 · primary_01.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 26, 2024 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-039129 · tm249879-3_4seq1.xml · derivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 26, 2024 22:11 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001104659-24-039129 · tm249879-3_4seq1.xml · derivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 1, 2024 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 83,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002239 · doc4.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,393 Underlying: Common Stock · 83,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the January 23, 2023 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the January 23, 2023 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 40,093 | $4.26 | $170,796.18 |
DisclosureSEC source: 0001209191-24-002239 · doc4.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,104 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 22:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 83,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002239 · doc4.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 249,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004855 · doc4.xml · derivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,590 Underlying: Common Stock · 249,590 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:06 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 290,700 | $0.00 Strike: $11.92 | $0.00 |
DisclosureSEC source: 0001209191-23-004855 · doc4.xml · derivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,700 Underlying: Common Stock · 290,700 shares Expires 2033-01-23 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") 2023 Inducement Plan (the "Plan") will vest on the first anniversary of the January 23, 2023 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 40,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-22-008696 · form4-08162022_010808.xml · derivative · entry 4 Jacobs John C · CIK 0001820836 · Director · PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,751 Underlying: Common Stock · 40,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 909 | $51.76 | $47,053.11 |
DisclosureSEC source: 0001415889-22-008696 · form4-08162022_010808.xml · nonDerivative · entry 3 Jacobs John C · CIK 0001820836 · Director · PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.56 to $52.05. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 39,091 | $51.05 | $1,995,759.73 |
DisclosureSEC source: 0001415889-22-008696 · form4-08162022_010808.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 909 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.56 to $51.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 40,000 | $8.22 | $328,800.00 |
DisclosureSEC source: 0001415889-22-008696 · form4-08162022_010808.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-071909 · tm2218582-1_4seq1.xml · derivative · entry 4 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,751 Underlying: Common Stock · 15,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 800 | $46.13 | $36,906.96 |
DisclosureSEC source: 0001104659-22-071909 · tm2218582-1_4seq1.xml · nonDerivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.19. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 14,200 | $45.38 | $644,370.44 |
DisclosureSEC source: 0001104659-22-071909 · tm2218582-1_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.78. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $8.22 | $123,300.00 |
DisclosureSEC source: 0001104659-22-071909 · tm2218582-1_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 20:16 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-071014 · tm2218405-1_4seq1.xml · derivative · entry 4 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,751 Underlying: Common Stock · 25,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 20:16 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 15,197 | $44.53 | $676,675.30 |
DisclosureSEC source: 0001104659-22-071014 · tm2218405-1_4seq1.xml · nonDerivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $44.89. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 20:16 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 9,803 | $43.63 | $427,735.28 |
DisclosureSEC source: 0001104659-22-071014 · tm2218405-1_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,197 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.02 to $44.01. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 20:16 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 25,000 | $8.22 | $205,500.00 |
DisclosureSEC source: 0001104659-22-071014 · tm2218405-1_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:23 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-035613 · tm228148-5_4seq1.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,751 Underlying: Common Stock · 15,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:23 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 15,000 | $45.32 | $679,821.00 |
DisclosureSEC source: 0001104659-22-035613 · tm228148-5_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.66. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:23 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $8.22 | $123,300.00 |
DisclosureSEC source: 0001104659-22-035613 · tm228148-5_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-034442 · tm228148-4_4seq1.xml · derivative · entry 5 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,751 Underlying: Common Stock · 25,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 930 | $43.47 | $40,427.10 |
DisclosureSEC source: 0001104659-22-034442 · tm228148-4_4seq1.xml · nonDerivative · entry 4 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.35 to $43.77. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 11,614 | $42.66 | $495,474.15 |
DisclosureSEC source: 0001104659-22-034442 · tm228148-4_4seq1.xml · nonDerivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.34 to $43.33. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 12,456 | $42.06 | $523,870.71 |
DisclosureSEC source: 0001104659-22-034442 · tm228148-4_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,544 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.34 to $42.33. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 25,000 | $8.22 | $205,500.00 |
DisclosureSEC source: 0001104659-22-034442 · tm228148-4_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 18,053 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-001475 · tm221863-1_4seq1.xml · derivative · entry 6 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,751 Underlying: Common Stock · 18,053 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 251,801 shares, and will vest with respect to the remainder of the shares on October 1, 2022. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 18,053 | $45.15 | $815,049.62 |
DisclosureSEC source: 0001104659-22-001475 · tm221863-1_4seq1.xml · nonDerivative · entry 4 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.70. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 18,053 | $8.22 | $148,395.66 |
DisclosureSEC source: 0001104659-22-001475 · tm221863-1_4seq1.xml · nonDerivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.